Author

Kaberi Das

The University of Texas MD Anderson Cancer CenterORCID 0000-0003-4702-0386Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genetics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Koichi TakahashiiD· 2 shared Sanam LoghaviiD· 2 shared Anna MalovannayaiD· 1 shared Antrix JainiD· 1 shared Branko CuglievaniD· 1 shared Christine E. Birdwell· 1 shared Christopher Peter MilliD· 1 shared Christopher R. FlowersiD· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Koichi TakahashiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyBloodPeer-reviewedMar 4, 2024

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

Warren C. Fiskus, Jessica C. Piel, Michael P. Collins…·Kapil N. Bhalla

This study shows that FHD-286, a BRG1/BRM inhibitor, reduces AML burden and improves survival when combined with Menin or BET inhibitors in xenograft models of AML with MLL1r or mtNPM1.

49 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky

GeneticsbioRxivPreprintSep 28, 2021

Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapy

Neeraj Y. Saini, David M. Swoboda, Uri Greenbaum…·Koichi Takahashi

This study finds that clonal hematopoiesis mutations, particularly in DNMT3A, TET2, and ASXL1, are linked to increased toxicity in patients undergoing anti-CD19 CAR T-cell therapy for large B-cell lymphoma.

DOI 10.1101/2021.09.28.461858

humanwhole-exome sequencing

𝕏 PostBluesky